Importance of Secondary Screening With Clinical Isolates for Anti-Leishmania Drug Discovery

Scientific Reports - United Kingdom
doi 10.1038/s41598-018-30040-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A ReplicativeIn VitroAssay for Drug Discovery Against Leishmania Donovani

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2016English

Screening for Drug Discovery: The Leading Question

Nature
Multidisciplinary
2002English

Role of Aquaglyceroporin (AQP1) Gene and Drug Uptake in Antimony-Resistant Clinical Isolates of Leishmania Donovani

American Journal of Tropical Medicine and Hygiene
MedicineVirologyParasitologyInfectious Diseases
2008English

Importance and Hurdles to Drug Discovery for Neurological Disease

Annals of Neurology
Neurology
2013English

mTOR Mediated Anti-Cancer Drug Discovery

Drug Discovery Today: Therapeutic Strategies
2009English

‘Big Data’ Approaches for Novel Anti-Cancer Drug Discovery

Expert Opinion on Drug Discovery
Drug Discovery
2017English

Genetic Heterogeneity in Clinical Isolates of Leishmania Donovani From India

Journal of Clinical Microbiology
Microbiology
2011English

Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania Donovani

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2011English

High Content Screening for Drug Discovery From Traditional Chinese Medicine

Chinese Medicine
Alternative MedicinePharmacologyComplementary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy